Long-term remission following esketamine nasal spray sessions in a patient with severe and highly treatment-resistant depression: a single-case report.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
11 Jul 2023
11 Jul 2023
Historique:
medline:
8
8
2023
pubmed:
8
8
2023
entrez:
8
8
2023
Statut:
aheadofprint
Résumé
About 30% of patients with major depressive disorder have treatment-resistant depression (TRD). Recently, intranasal esketamine was approved as a treatment option after the failure of two antidepressant trials. We report a patient with multiresistant depression that was successfully and safely treated with esketamine nasal spray. This 31-year-old inpatient with severe, chronic, and multi-TRD received an acute course of intranasal esketamine (84 mg). Previously, 14 different antidepressants, alone or in potentiation, and several neurostimulation techniques had been unsuccessful. Over 20 bi-weekly sessions, she had no significant adverse effects and was stabilized into remission. During the maintenance phase and 1 year after, she continues to be stable. This case report provides an example of a patient with severe TRD that showed significant improvement after treatment with intranasal esketamine.
Identifiants
pubmed: 37551607
doi: 10.1097/YIC.0000000000000482
pii: 00004850-990000000-00075
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Brendle M, Ahuja S, Valle MD, Moore C, Thielking P, Malone DC, et al. (2022). Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study. J Comp Eff Res 11:1323–1336.
Capuzzi E, Caldiroli A, Capellazzi M, Tagliabue I, Marcatili M, Colmegna F, et al. (2021). Long-term efficacy of intranasal esketamine in treatment-resistant major depression: a systematic review. Int J Mol Sci 22:9338.
Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. (2018). Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 75:139–148.
Dunner DL, Fugate RM, Demopulos CM (2020). Safety and efficacy of esketamine nasal spray in a depressed patient who was being treated with tranylcypromine: a case report. Neurol Psychiatry Brain Res 36:30–31.
Karkare S, Zhdanava M, Pilon D, Nash AI, Morrison L, Shah A, et al. (2022). Characteristics of real-world commercially insured patients with treatment-resistant depression initiated on esketamine nasal spray or conventional therapies in the United States. Clin Ther 44:1432–1448.
Levinta A, Meshkat S, McIntyre RS, Ho C, Lui LMW, Lee Y, et al. (2022). The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: a systematic review. J Affect Disord 318:139–149.
Martinotti G, Vita A, Fagiolini A, Maina G, Bertolino A, Dell'Osso B, et al.; REAL-ESK Study Group (2022). Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study). J Affect Disord 319:646–654.
Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 176:428–438.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917.
Samalin L, Rothärmel M, Mekaoui L, Emeline G-W, Marie-Alix C, et al. (2022). Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme. Int J Psychiatry Clin Pract 26:352–362.